ReGen Biologics (OTC: RGBI) will exhibit the company's products at
the Arthroscopy Association of North America (AANA) meeting, being
held this week in San Francisco.
Additionally, data from its CMI(TM) product clinical trial will be
highlighted in two podium presentations and two "e-posters" as part of
the scientific program offered to attending surgeons.
The first presentation focuses on the correlation between tissue
loss and clinical symptoms, function and activity levels following
meniscectomy. The second underscores the decreased rate of
re-operations for chronic patients receiving a collagen meniscus
implant. Both presentations are scheduled for this afternoon.
The e-posters are available for review throughout the meeting. One
features the latest suture techniques being used for fixation of the
collagen meniscus implant and the other documents new tissue growth
and increased activity level in patients two years following a
collagen meniscus implant procedure.
"The AANA meeting provides an excellent forum for ReGen management
and clinical collaborators to meet and discuss our latest clinical
data," said Gerald E. Bisbee, Jr., Ph.D., Chairman and Chief Executive
Officer of ReGen Biologics.
Copies of presentation and poster abstracts will be available on
the ReGen corporate website following the completion of the AANA
annual meeting at www.regenbio.com.
The stated goal of the AANA is to promote, encourage, support and
foster through continuing medical education functions, the development
and dissemination of knowledge in the discipline of arthroscopic
surgery. For more information on the annual meeting, or scheduled
presentations visit www.aana.org.
About ReGen Biologics, Inc.:
ReGen Biologics is an orthopedic products company that develops,
manufactures and markets innovative tissue growth and repair products
for U.S. and global markets. ReGen's patented collagen scaffold
technology includes applications in orthopedics, general surgery,
spine, cardiovascular and drug delivery. ReGen's first approved
product using its collagen scaffold technology is the CMI(TM), a
meniscus application, which is cleared for sale in Europe and marketed
through ReGen's European subsidiary, ReGen Biologics AG. ReGen has
submitted a 510(k) to the FDA in the U.S. for clearance of the CMI.
ReGen is headquartered in Franklin Lakes, NJ and manufactures its
collagen scaffold products in its ISO Certified facility located in
Redwood City, CA. For more information on ReGen, visit
www.regenbio.com.
This press release contains forward-looking statements within the
meaning of the Safe Harbor Provisions of the Private Securities
Litigation Reform Act of 1995. Such statements are based on the
current expectations and beliefs of the management of ReGen and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements, including those discussed in the Risk
Factors section of ReGen's 2006 annual report on Form 10-K and
additional filings with the SEC. ReGen's filings with the SEC are
available to the public at the Company's website at
http://www.regenbio.com, from commercial document-retrieval services
and at the Web site maintained by the SEC at http://www.sec.gov.
